We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Federal Appeals Court to Review $236 Million ‘Skinny Labeling’ Ruling Against Teva
Federal Appeals Court to Review $236 Million ‘Skinny Labeling’ Ruling Against Teva
Teva Pharmaceuticals has another chance to argue it shouldn’t have to pay $235.5 million in damages to GlaxoSmithKline for patent infringement, as the full U.S. Court of Appeals for the Federal Circuit has agreed to review a ruling to that effect.